scholarly journals Highlights of Natural Products in Prostate Cancer Drug Discovery

10.5772/27401 ◽  
2011 ◽  
Author(s):  
Jorge A. R. Salvador ◽  
Vania M.
Keyword(s):  
Prostate Cancer ◽  
Natural Products ◽  
Drug Discovery ◽  
Cancer Drug ◽  
Cancer Drug Discovery

The use of natural products in colorectal cancer drug discovery

2015 ◽  
Vol 10 (4) ◽  
pp. 411-426 ◽  
Author(s):  
Koh Miura ◽  
Masayuki Satoh ◽  
Makoto Kinouchi ◽  
Kuniharu Yamamoto ◽  
Yasuhiro Hasegawa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Natural Products ◽  
Drug Discovery ◽  
Cancer Drug ◽  
Cancer Drug Discovery

Natural Products and Cancer Drug Discovery

2013 ◽  
Vol 9 (7) ◽  
pp. 949-950
Author(s):  
David J Newman
Keyword(s):  
Natural Products ◽  
Drug Discovery ◽  
Cancer Drug ◽  
Cancer Drug Discovery

What Makes Species Productive of Anti-Cancer Drugs? Clues from Drugs’ Species Origin, Druglikeness, Target and Pathway

2019 ◽  
Vol 19 (2) ◽  
pp. 194-203 ◽  
Author(s):  
Xiaofeng Li ◽  
Xiaoxu Li ◽  
Yinghong Li ◽  
Chunyan Yu ◽  
Weiwei Xue ◽  
...  
Keyword(s):  
Natural Products ◽  
Drug Discovery ◽  
Phylogenetic Tree ◽  
Drug Approval ◽  
Cancer Drug ◽  
Cancer Drugs ◽  
Phylogenetic Distribution ◽  
Cancer Drug Discovery ◽  
Anti Cancer ◽  
Novel Drug

Background:Despite the substantial contribution of natural products to the FDA drug approval list, the discovery of anti-cancer drugs from the huge amount of species on the planet remains looking for a needle in a haystack. Objective: Drug-productive clusters in the phylogenetic tree are thus proposed to narrow the searching scope by focusing on much smaller amount of species within each cluster, which enable prioritized and rational bioprospecting for novel drug-like scaffolds. However, the way anti-cancer nature-derived drugs distribute in phylogenetic tree has not been reported, and it is oversimplified to just focus anti-cancer drug discovery on the drug-productive clusters, since the number of species in each cluster remains too large to be managed.Objective:Drug-productive clusters in the phylogenetic tree are thus proposed to narrow the searching scope by focusing on much smaller amount of species within each cluster, which enable prioritized and rational bioprospecting for novel drug-like scaffolds. However, the way anti-cancer nature-derived drugs distribute in phylogenetic tree has not been reported, and it is oversimplified to just focus anti-cancer drug discovery on the drug-productive clusters, since the number of species in each cluster remains too large to be managed.Methods:In this study, 260 anti-cancer drugs approved in the past 70 years were comprehensively analyzed by hierarchical clustering of phylogenetic distribution.Results:207 out of these 260 drugs were derived from or inspired by the natural products isolated from 58 species. Phylogenetic distribution of those drugs further revealed that nature-derived anti-cancer drugs originated mostly from drug-productive families that tend to be clustered rather than scattered on the phylogenetic tree. Moreover, based on their productivity, drug-producing species were categorized into productive (CPS), newly emerging (CNS) and lessproductive (CLS). Statistical significances in druglikeness between drugs from CPS and CLS were observed, and drugs from CNS were found to share similar drug-like properties to those from CPS.Conclusion:This finding indicated a great raise in drug approval standard, which suggested us to focus bioprospecting on the species yielding multiple drugs and keeping productive for long period of time.

Natural Products: Promising Resources for Cancer Drug Discovery

2012 ◽  
Vol 12 (1) ◽  
pp. 49-75 ◽  
Author(s):  
Susmita Mondal ◽  
Santu Bandyopadhyay ◽  
Mrinal K. Ghosh ◽  
Sibabrata Mukhopadhyay ◽  
Siddhartha Roy ◽  
...  
Keyword(s):  
Natural Products ◽  
Drug Discovery ◽  
Cancer Drug ◽  
Cancer Drug Discovery
Sign in / Sign up

Export Citation Format

Share Document